Pool J L
Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Br J Clin Pract. 1996 Apr-May;50(3):154-63.
Doxazosin, a selective alpha 1-adrenoceptor antagonist, is an established first-line antihypertensive agent that is being introduced for the management of benign prostatic hyperplasia. Hypertension and benign prostatic hyperplasia are linked by the sympathetic nervous system, which has an aetiologic role in both conditions. The alpha 1-adrenoceptor is a mediator of increased tension, both in vascular and prostatic smooth muscle. Studies have shown that doxazosin, through its balanced action on alpha 1-adrenoceptor subtypes, reduces blood pressure and improves other risk factors for coronary heart disease, such as lipid profile, insulin sensitivity, left ventricular hypertrophy, platelet aggregation and fibrinolysis. Data are now accumulating to show that doxazosin improves urinary flow rates and symptoms in patients with benign prostatic hyperplasia. These effects have been demonstrated in controlled clinical studies, within weeks, and long term. Since hypertension and benign prostatic hyperplasia are widespread and often undiagnosed in the community, particularly with increasing age, doxazosin may be a particularly appropriate therapy for the considerable number of older men with both conditions.
多沙唑嗪是一种选择性α1肾上腺素能受体拮抗剂，是一种公认的一线抗高血压药物，现正被用于治疗良性前列腺增生。高血压和良性前列腺增生通过交感神经系统相联系，交感神经系统在这两种病症中均具有病因学作用。α1肾上腺素能受体是血管和平滑肌张力增加的介质。研究表明，多沙唑嗪通过对α1肾上腺素能受体亚型的平衡作用，可降低血压，并改善冠心病的其他危险因素，如血脂谱、胰岛素敏感性、左心室肥厚、血小板聚集和纤维蛋白溶解。目前越来越多的数据表明，多沙唑嗪可改善良性前列腺增生患者的尿流率和症状。这些作用已在对照临床研究中得到证实，无论是在数周内还是长期。由于高血压和良性前列腺增生在社区中广泛存在且常常未被诊断出来，尤其是随着年龄的增长，多沙唑嗪可能是治疗大量同时患有这两种病症的老年男性的特别合适的疗法。
